Two Sigma Advisers’s ImmunityBio IBRX Stock Holding History

Two Sigma Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,142,256	Closed	-$2.26M	–	1016
2025 Q4	$2.26M	Buy	1,142,256 +1,024,600	+871%	+$2.32M	﹤0.01%	1138
2025 Q3	$289K	Buy	+117,656	New	+$303K	﹤0.01%	2004
2022 Q3	–	Sell	-15,200	Closed	-$57K	–	2638
2022 Q2	$57K	Sell	15,200 -8,200	-35%	-$32.9K	﹤0.01%	2463
2022 Q1	$131K	Sell	23,400 -4,700	-17%	-$28.8K	﹤0.01%	2457
2021 Q4	$171K	Buy	+28,100	New	+$211K	﹤0.01%	2321
2020 Q4	–	Sell	-429,233	Closed	-$2.98M	–	2477
2020 Q3	$2.98M	Buy	+429,233	New	+$4.28M	0.01%	962

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Two Sigma Advisers's IBRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 1,142,256 shares — an estimated $2.26M sold.

Two Sigma Advisers first reported a position in IBRX in Q3 2020 and held it in 6 quarters. The position peaked at $2.98M in Q3 2020. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Two Sigma Advisers reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 1,142,256 ImmunityBio shares in Q1 2026, an estimated $2.26M.
Two Sigma Advisers first reported a position in ImmunityBio in Q3 2020 and held it in 6 quarters.
Two Sigma Advisers's ImmunityBio position peaked at $2.98M in Q3 2020.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.